NSE filing, NSE: INDSWFTLAB. Summary written from the filing by ALFA Finder's alert engine.
Ind-Swift Laboratories Ltd: key numbers
- Share price
- ₹368.20
- Market cap
- ₹3,202 Cr
- Revenue (annual)
- ₹649.1 Cr
- Net profit (annual)
- ₹43.12 Cr
- P/E (TTM)
- 38.3×Sector 48.7×
- Promoter holding
- 42.93%+0.00% QoQ
- FII holding
- 10.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ind-Swift Laboratories Ltd
All →Ind-Swift Laboratories Q2 FY27 Results: Net Profit ₹34.2 Cr, Up 327.5% YoY
Ind-Swift Laboratories Ltd reported revenue from operations of ₹240.5 Cr (+51.6% YoY) and net profit of ₹34.2 Cr (+327.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹34.2 Cr · +327.5% YoY
Ind-Swift Laboratories Board Meeting Date
Ind-Swift Laboratories Ltd. scheduled a board meeting for October 29, 2026, to consider and approve the standalone and consolidated financial results for the quarter and half-year.
Ind-Swift Laboratories Convertible Warrants
Essix Biosciences Limited acquired 14,00,000 equity shares of Ind-Swift Laboratories Limited following the conversion of fully convertible warrants. The company disclosed this under SEBI regulations.
Ind-Swift Laboratories Capital Structure Change
Ind-Swift Laboratories allotted 14,00,000 equity shares upon conversion of warrants at Rs. 196 each. The allotment follows a previously approved preferential issue.
- Value
- ₹27.44 Cr
Ind-Swift Laboratories Capital Structure Change
Ind-Swift Laboratories allotted 14 lakh equity shares upon converting warrants for Essix Biosciences Limited, receiving ₹20.58 Crore. This increases the company's paid-up equity share capital.
- Value
- ₹20.58 Cr
Ind-Swift Laboratories Annual General Meeting
Ind-Swift Laboratories Limited held its 31st Annual General Meeting on September 30, 2026. Members approved audited financial statements and director appointments.
Other results update announcements
All →Narayana Hrudayalaya Results Update
Narayana Hrudayalaya reported Q2 FY27 consolidated revenue of Rs 28,440 Mn, up 73% YoY. PAT rose 16.6% to Rs 3,012 Mn, with the UK acquisition boosting revenue.
Corona Remedies Results Update
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
Acme Universal Safezone 9 Results Update
Acme Universal Safezone 9 reported H1FY27 revenue up 16.09% to ₹119.93 crore. EBITDA rose 54.62% and PAT turned to ₹7.02 crore profit.
Radiowalla Network Results Update
Radiowalla Network reported H1 FY27 revenue of ₹107.93 million, up 7% year-on-year. EBITDA rose to ₹8.16 million, with an 8% margin.
Artemis Medicare Services Results Update
Artemis Medicare reported Q2 FY27 consolidated revenue up 13.2% and PAT up 3.7% year-on-year. Adjusted EBITDA rose 22.7%, with the Raipur hospital launched in July 2026.
Advait Energy Transitions Results Update
Advait Energy reported Q2 FY27 consolidated revenue of ₹220.9 crore, up 40.8%, and PAT of ₹19.18 crore, up 88.5%. Its order book reached ₹1,574.8 crore.
- Order book
- ₹1,575 Cr